Inovio Pharmaceuticals Statistics Share Statistics Inovio Pharmaceuticals has 53.14M
shares outstanding. The number of shares has increased by 41.25%
in one year.
Shares Outstanding 53.14M Shares Change (YoY) 41.25% Shares Change (QoQ) 0.02% Owned by Institutions (%) 35.22% Shares Floating 52.86M Failed to Deliver (FTD) Shares 818 FTD / Avg. Volume 0.03%
Short Selling Information The latest short interest is 7.49M, so 14.1% of the outstanding
shares have been sold short.
Short Interest 7.49M Short % of Shares Out 14.1% Short % of Float 14.17% Short Ratio (days to cover) 3.61
Valuation Ratios The PE ratio is -0.46 and the forward
PE ratio is -1.61.
Inovio Pharmaceuticals's PEG ratio is
0.01.
PE Ratio -0.46 Forward PE -1.61 PS Ratio 228.26 Forward PS 9.3 PB Ratio 0.73 P/FCF Ratio -0.48 PEG Ratio 0.01
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Inovio Pharmaceuticals.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 2.77,
with a Debt / Equity ratio of 0.17.
Current Ratio 2.77 Quick Ratio 2.77 Debt / Equity 0.17 Debt / EBITDA -0.11 Debt / FCF -0.11 Interest Coverage -632.05
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $1.63K Profits Per Employee $-800.4K Employee Count 134 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax -107.15B Effective Tax Rate 99.9%
Stock Price Statistics The stock price has increased by -57.68% in the
last 52 weeks. The beta is 1.63, so Inovio Pharmaceuticals's
price volatility has been higher than the market average.
Beta 1.63 52-Week Price Change -57.68% 50-Day Moving Average 2 200-Day Moving Average 1.98 Relative Strength Index (RSI) 56.59 Average Volume (20 Days) 2,388,271
Income Statement In the last 12 months, Inovio Pharmaceuticals had revenue of 217.76K
and earned -107.25M
in profits. Earnings per share was -3.95.
Revenue 217.76K Gross Profit -2.91M Operating Income -112.4M Net Income -107.25M EBITDA -103.95M EBIT -107.08M Earnings Per Share (EPS) -3.95
Full Income Statement Balance Sheet The company has 65.81M in cash and 11.87M in
debt, giving a net cash position of 53.95M.
Cash & Cash Equivalents 65.81M Total Debt 11.87M Net Cash 53.95M Retained Earnings -1.73B Total Assets 68.24M Working Capital 20.99M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -104.08M
and capital expenditures -487.83K, giving a free cash flow of -104.56M.
Operating Cash Flow -104.08M Capital Expenditures -487.83K Free Cash Flow -104.56M FCF Per Share -3.85
Full Cash Flow Statement Margins Gross margin is -1337.41%, with operating and profit margins of -51616.91% and -49254.27%.
Gross Margin -1337.41% Operating Margin -51616.91% Pretax Margin -49254269% Profit Margin -49254.27% EBITDA Margin -47735.19% EBIT Margin -51616.91% FCF Margin -48019.06%
Dividends & Yields INO does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for INO is $9,
which is 262.9% higher than the current price. The consensus rating is "Buy".
Price Target $9 Price Target Difference 262.9% Analyst Consensus Buy Analyst Count 5
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Jan 25, 2024. It was a
backward
split with a ratio of 1:12.
Last Split Date Jan 25, 2024 Split Type backward Split Ratio 1:12
Scores Altman Z-Score -1248.61 Piotroski F-Score 1
